Table 1 Demographics and clinical characteristics of patients with COVID-19

Characteristics

Age (yr.)—median (Interquartile range [IQR])

60 (50–68)

57(45–65)

63 (54–71)

 < 0.001

Sex– no. (%)

–

–

–

1

 Male

1,493 (50.5%)

728 (50.6%)

765 (50.5%)

 Female

1,461 (49.5%)

711 (49.4%)

750 (49.5%)

Initial temperature (℃)

– median (IQR)

–

–

–

0.002

  ≤ 37.3– no. (%)

2,833 (95.9%)

1,398 (97%)

1,435 (94.7%)

–

 37.3–38– no. (%)

85 (2.9%)

25 (2%)

60 (4%)

–

 38 -39– no. (%)

35 (1.17%)

16 (1%)

19(1.2%)

–

  > 39– no. (%)

1 (0.03%)

0 (0%)

1 (0.1%)

–

Comorbidities—no. (%)

 Hypertension

889 (30%)

348 (24%)

541 (36%)

 < 0.001

 Diabetes

401 (14%)

159 (11%)

242 (16%)

 < 0.001

 Cardiovascular disease

330 (11%)

104 (7%)

226 (15%)

 < 0.001

 Cerebrovascular disease

118 (4%)

34 (2%)

84 (6%)

 < 0.001

 Cancer

74 (3%)

19 (1%)

55 (4%)

 < 0.001

 Chronic obstructive pulmonary disease

139 (5%)

40 (3%)

99 (7%)

 < 0.001

 Chronic renal disease

47 (2%)

14 (1%)

33 (2%)

0.012

 Chronic liver disease

76 (3%)

36 (3%)

40 (3%)

0.817

 Immunodeficiency

9 (0%)

4 (0%)

5 (0%)

1

Respiratory rate—median (IQR)

–

–

–

 < 0.001

  > 24 breaths per min– no. (%)

132 (4%)

14 (1%)

118 (8%)

–

  ≤ 24 breaths per min–no. (%)

2,820 (95%)

1,425 (99%)

1,395 (92%)

–

Hospital stays—median (IQR)

13 (8–19)

12 (8–17)

14 (8–22)

 < 0.001

Death—no. (%)

59(2%)

0 (0%)

59(4%)

 < 0.001

Clinical symptoms—no. (%)

 Fever

2,149 (73%)

1,032 (72%)

1,117 (74%)

0.231

 Cough

2,062 (70%)

992 (69%)

1,070 (71%)

0.336

 Shortness of breath

1302 (44%)

608 (42%)

694 (46%)

0.05

 Chest tightness

1,137 (38%)

517 (36%)

620 (41%)

0.006

 Fatigue

669 (23%)

279 (19%)

390 (26%)

 < 0.001

 Muscle soreness

118 (4%)

29 (2%)

89 (6%)

 < 0.001

 Headache

17 (1%)

13 (1%)

4 (0%)

0.027

 Dizziness

26 (1%)

14 (1%)

12 (1%)

0.695

 Nausea

22 (1%)

12 (1%)

10 (1%)

0.671

 Vomiting

22 (1%)

11 (1%)

11 (1%)

1

 Diarrhea

64 (2%)

34 (2%)

30 (2%)

0.528

Radiological findings (N = 2567)—no. (%)

 Blurred edges

304 (12%)

118 (9.6%)

186 (14%)

 < 0.001

 Lymph node enlargement

30 (1.2%)

18 (1.5%)

12 (0.9%)

0.202

 Ground glass opacity

2324 (91%)

1109 (90%)

1215 (91%)

0.304

 Cystic change

209 (8.2%)

81 (6.6%)

128 (9.6%)

0.006

 Airway obstruction

4 (0.16%)

2 (0.16%)

2 (0.15%)

1

 Consolidation

332 (13%)

115 (9.4%)

217 (16%)

 < 0.001

 Fine reticular opacity

56 (2.2%)

17 (1.4%)

39 (2.9%)

0.01

 Lung texture increase

1529 (60%)

734 (60%)

795 (60%)

0.968

 Intralobular septal thickening

14 (0.55%)

4 (0.33%)

10 (0.75%)

0.183

 Pleural thickening

221 (8.6%)

72 (5.9%)

149 (11%)

 < 0.001

 Pleural effusion

205 (8%)

34 (2.8%)

171 (13%)

 < 0.001

 Bronchiectasis

53 (2.1%)

17 (1.4%)

36 (2.7%)

0.025

Viral load of throat swabs (N = 1476)—median (IQR)

 ORF1ab

37.7 (34.51–40.08)

37.85 (34.85–40.05)

37.62 (34.07–40.15)

0.258

N

36.33 (33.77–37.82)

36.4 (34.08–37.77)

36.28

(33.5–37.91)

0.762

Anti-SARS-Cov-2 IgG and IgM level—median (IQR)

 IgG level

139.49 (73.93–181.24)

141.33

(74.82–180.45)

137.64 (73.88–181.45)

0.864

 IgM level

26.88

(8.38–66.74)

26.46

(8.13–62.5)

27.32

(8.52–68.62)

0.337